Following the signing of a letter of intent for a sales agreement with Adherium, Monaghan Medical said that it will launch Adherium’s Hailie digital inhaler monitoring platform in the US. The Hailie sensor was approved by the FDA for US over the counter sales in July 2018, and Adherium launched the sensor in August of that year.
Monaghan’s parent company, Trudell Medical Limited, invested $1.1 million in Adherium in a recent financing round and currently has a 17% stake in the company.
Adherium has recently made numerous management changes, announcing the appointments of Mike Motion as CEO, James Ward Lilley as Chairman of the Board, and Jane Lapon as Head of Global Market Access & Reimbursement so far this year. The company also recently announced a deal with HGE Health for COPD disease management for patients in several US states, as well as a development deal with Planet Innovation.
Monaghan VP of Sales and Marketing Bill Seitz said, “We are excited to bring this technology to our customers and provide them with a platform to help guide treatment decisions based on real-life data. Monaghan is dedicated to improving the lives of people with respiratory conditions, and our partnership with Adherium will allow us to advance that goal. Our strong customer relationships provide Adherium with a unique opportunity to bring the Hailie platform to targeted facilities across the US. It will complement our current product offering and provide us with the opportunity to expand into the digital space, while offering clinicians new ways to manage their patients remotely.”
Trudell Medical Limited CEO Gerald Slemko, who is also President of Monaghan Medical, commented, “This is a big first step in bringing extended offerings to our current and future customers. There is a real synergy between the Hailie platform and the Monaghan portfolio, including our market-leading AeroChamber brand of valved holding chamber. This as a real opportunity especially for uncontrolled, pediatric and adult patients, initially focused in asthma, where there is a high burden of disease and consumption of healthcare time and costs in secondary/tertiary care.”
Adherium CEO Mike Motion said, “This is a key second commercial announcement for Adherium in the US. With Monaghan working with us in specialty sales and HGE focussing in disease management with payers and providers, Adherium has a very strong integrated commercial approach. A definitive agreement with Monaghan has significant financial value.”
Read the Monaghan Medical press release.
